Home > Boards > Free Zone > User's Groups > Marijuana - Public Weed Stocks & Analysis (WEED)

$KALY - Kali-Extracts COPD Research Targeting $14 Billion

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Golden_Cross Member Profile
Member Level 
Followed By 823
Posts 32,962
Boards Moderated 49
Alias Born 10/05/05
160x600 placeholder
Golden_Cross Member Level  Saturday, 01/26/19 10:14:16 AM
Re: None
Post # of 39752 
$KALY - Kali-Extracts COPD Research Targeting $14 Billion Treatment Market To Be Featured In Online Corporate Update Next Week
Date : 01/25/2019 @ 10:00AM
Source : InvestorsHub NewsWire
Stock : Kali, Inc. (PN) (KALY)
Quote : 0.0114 0.0008 (7.55%) @ 3:59PM

KALY - Kali-Extracts COPD Research Targeting $14 Billion Treatment Market To Be Featured In Online Corporate Update Next Week
Print
Alert
Dallas, TX -- January 25, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced an online corporate update scheduled for Wednesday next week on January 30, 2019. The presentation will include updates on KALY’s developments with Puration, Inc, (USOTC: PURA) (“PURA”) and Generex Biotechnology, Inc. (OTCBB: GNBT). The presentation will also include updates on the company’s Hemp4mula product developments. The highlight of the presentation will feature the latest on the company’s research on treatments for Chronic Obstructive Pulmonary Disease (COPD). KALY has completed an in vitro genomics study to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients. Favorable results prompted the launch of a physiological study whose results will be released later this quarter. The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.

Goldman Small Cap Research Report published an analyst research report on KALY on January 8th, 2019 that highlights KALY’s cannabis pharmaceutical value. The report is available under “research” on the OTCMarkets website. The research report is the first report from Goldman Small Cap Research as part of an ongoing research engagement. The report outlines the company’s current positioning and potential, upcoming milestones. The report is intended to augment the current information available on the OTCMarkets website. The report is also available to read or download, along with associated disclosures and disclaimers, at www.GoldmanResearch.com.

To learn more about the company visit https://www.kali-extracts.com/

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.

CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459

Lets exchange follow marks and share market moving information today!
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist